← Back to screener

REGENERON PHARMACEUTICALS, INC. REGN

Rank #540 · Nasdaq · $87.2B market cap
Audited by PricewaterhouseCoopers LLP, no going-concern flag in the latest filing.
Score
63.2
P/E
22.1
P/B
3.85
ROE
17.4%
Op. Margin
30.9%
Debt Ratio
37%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★★☆☆
Average

P/E 22.1x, P/B 3.85x. Ranks in the top 44% of the universe.

Profitability ★★★★☆
Excellent

ROE 17.4%. Ranks in the top 17% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 37%. Ranks in the top 19% of the universe. Under 100% is generally considered a safe level.

Growth ★★★☆☆
Average

Revenue growth of 7.8% year over year. Ranks in the top 41% of the universe.

Profitability is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011$0.4B$-0.1B$-0.1B$0.4B-19.5133
2012$0.5B$-0.1B$-0.1B$0.4B-21.2211
2013$0.4B$-0.2B$-0.2B$0.5B-46.0158
2014$1.4B$0.5B$0.8B$0.5B33.2206
2015$2.1B$0.7B$0.4B$1.3B35.3102
2016$2.8B$0.8B$0.3B$2.0B29.299
2017$4.1B$1.3B$0.6B$2.6B30.599
2018$4.9B$1.3B$0.9B$3.7B27.472
2019$5.9B$2.1B$1.2B$4.4B35.467
2020$5.1B$2.5B$2.4B$6.1B49.360
2021$6.6B$2.2B$2.1B$8.8B33.770
2022$8.5B$3.6B$3.5B$11.1B42.160
2023$16.1B$8.9B$8.1B$11.0B55.759
2024$12.2B$4.7B$4.3B$18.8B38.938
2025$13.1B$4.0B$4.0B$22.7B30.937

← See the full screener